Cv Sciences, INC

CV Sciences held its 2026 Annual Meeting, electing three directors and ratifying its auditor, but failing to gain shareholder approval for a reverse stock split.

CV Sciences announced its first quarter 2026 financial results, reporting a revenue decrease to $3.2 million from $3.6 million in the prior year, attributed to regulatory challenges.

CV Sciences, Inc. has amended its convertible notes, adjusting the conversion price and extending maturity dates, impacting its financial obligations.

CV Sciences, Inc. reported fiscal year 2025 financial results, highlighting significant improvements in gross margin and adjusted EBITDA, despite a 12.2% decrease in annual revenue.

CV Sciences, Inc. announced its third quarter 2025 financial results, reporting a 16% revenue decrease and a widened adjusted EBITDA loss, while facing new federal hemp industry restrictions.

CV Sciences, Inc. has secured a $600,000 senior secured note, but received only $300,000 in net proceeds after significant discounts and fees, while its auditors issued a 'going concern' opinion.

CV Sciences, Inc. (CVSI) filed its Q2 2026 10-Q, revealing a 17.5% year-over-year revenue decline and a widening net loss, raising going concern doubts.

CV Sciences, Inc. reported a reduced net loss for Q3 and the first nine months of 2025, but faces significant challenges from new federal THC regulations and ongoing liquidity concerns.

CV Sciences, Inc. reported significantly reduced net and operating losses and positive cash flow from operations for the first half of 2025, despite a decline in product sales.

CV Sciences reports a decrease in net product sales for Q1 2025, alongside strategic cost reductions and ongoing efforts to secure additional funding.

CV Sciences reports a net loss for Q3 2024, with a slight decrease in revenue and ongoing efforts to manage costs and explore strategic opportunities.

CV Sciences reports a slight decrease in net product sales but improved gross margins in the second quarter of 2024, while also completing two strategic acquisitions.

CV Sciences reported a 12.2% drop in net product sales for 2025 and a 'substantial doubt' about its ability to continue as a going concern, despite improved gross margins and reduced operating losses.

CV Sciences' 2024 10-K filing reveals a year of strategic acquisitions, cost management, and mixed financial performance in the competitive consumer wellness market.

CV Sciences acquired Cultured Foods, a European plant-based food manufacturer, while reporting a slight decrease in net product sales but improved gross profit in its annual 10-K filing.

James Michael Corroon Jr., a director of CV Sciences, Inc., acquired 500,000 stock options on February 18, 2025.

Joerg Grasser, CFO of CV Sciences, Inc., reports the acquisition of 2,350,000 employee stock options.

CV Sciences CEO Joseph Dowling reports the acquisition of 3,000,000 employee stock options with an exercise price of $0.0375, vesting monthly over three years from February 18, 2025.

Director William McCorkle reports acquisition of 500,000 stock options in CV Sciences, Inc.

Director William McCorkle acquired 500,000 stock options in CV Sciences, Inc. on June 20, 2024.

Director James Michael Corroon Jr. of CV Sciences, Inc. reports acquiring 500,000 stock options on June 20, 2024.

CV Sciences, Inc. will hold its annual meeting of stockholders virtually on June 2, 2025, to vote on director elections, auditor ratification, executive compensation, and other business matters.

CV Sciences will hold its annual stockholders meeting virtually on June 3, 2024, to vote on director elections, auditor ratification, and executive compensation.